- You are here:
- Home »
- Blog »
- cervical cancer »
- AHCC and Cervical Cancer
AHCC and Cervical Cancer
AHCC and Cervical Cancer: What the Research Says- Active Hexose Correlated Compound (AHCC) is a nutritional supplement derived from the mycelia of the shiitake mushroom (Lentinula edodes). Over the past two decades, researchers have studied AHCC for its ability to support immune function, reduce viral infections, and potentially complement cancer therapy.
Because persistent human papillomavirus (HPV) infection is the primary cause of cervical cancer, research examining AHCC’s ability to help the body clear HPV has attracted significant attention.
This article reviews what current research says about AHCC and cervical cancer risk, HPV clearance, and immune support.
I am a long-term survivor of an incurable blood cancer called multiple myeloma. When I discovered that HPV increased my risk of an MM diagnosis, I decided to take AHCC in an effort to clear the HPV in my body.
When I was blogging about evidence-based therapies to support cancer patients, I wondered about AHCC and its effect on the side effects of cancer patients undergoing chemotherapy and radiation.
Below is an evidence-based overview of the potential pros and cons of AHCC supplementation specifically relevant to breast cancer patients, with active research links.
Feel free to scroll down the page and post a question or comment. I will reply to you ASAP.
Thanks,
David Emerson
Use of AHCC to Reduce Chemotherapy Side-Effects.
What Is AHCC?
AHCC is a standardized extract of cultured shiitake mushroom mycelia developed in Japan. It contains alpha-glucans and other compounds that may stimulate immune activity, including natural killer (NK) cells and T-cells.
Researchers have explored AHCC for several potential benefits:
- Supporting immune system activity
- Improving tolerance to chemotherapy
- Reducing infection risk in immunocompromised patients
- Enhancing clearance of certain viral infections
The most compelling evidence related to cervical cancer involves HPV infection, which causes the majority of cervical cancers worldwide.
AHCC and HPV Infection (The Main Driver of Cervical Cancer)
Persistent infection with high-risk HPV strains such as HPV-16 and HPV-18 is responsible for most cervical cancers.
Several studies have examined whether AHCC supplementation can help the immune system clear persistent HPV infections.
Human Clinical Trial
A randomized, double-blind, placebo-controlled Phase II study investigated AHCC in women with persistent high-risk HPV infection.
Key findings:
- Participants took 3 grams of AHCC daily
- 63.6% of women receiving AHCC cleared HPV infection
- Only 10.5% of placebo participants cleared the infection
Researchers concluded AHCC supplementation “supported the host immune system to eliminate persistent HPV infections.”
Study link:
https://pubmed.ncbi.nlm.nih.gov/35814366/
Full article:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9256908/
How AHCC May Work
Researchers believe AHCC may help clear HPV infection by modulating immune signaling.
Possible mechanisms include:
- Increasing T-cell activity
- Enhancing natural killer cell function
- Regulating interferon signaling (particularly IFN-β) linked to viral persistence
Laboratory and animal studies have shown that AHCC may suppress elevated interferon-beta levels associated with chronic viral infections, allowing the immune system to eliminate HPV-infected cells.
Why HPV Clearance Matters
Clearing persistent HPV infection is important because chronic infection can lead to:
- Cervical dysplasia (precancerous lesions)
- Cervical intraepithelial neoplasia (CIN)
- Cervical cancer
If AHCC helps some patients clear persistent HPV infection, it may reduce the long-term risk of cervical cancer development.
However, it is important to note:
- AHCC is not a proven treatment for cervical cancer
- More clinical trials are needed
- HPV vaccination remains the most effective prevention strategy
Potential Integrative Role of AHCC
Some oncologists and integrative practitioners explore AHCC as a complementary therapy because it may:
- Support immune function during treatment
- Help clear HPV infections
- Improve resilience to infection during chemotherapy
Still, AHCC should be considered a complementary therapy—not a substitute for medical treatment.
Patients should always discuss supplements with their oncology team before starting them.
The Bottom Line
Current research suggests AHCC may support immune activity and help some patients clear persistent HPV infections, which are strongly linked to cervical cancer.
Promising early clinical results show:
- Significant HPV clearance rates
- Good safety profile
- Potential immune-modulating effects
Potential advantages
- Immune system support (NK cells, T cells)
- May reduce chemotherapy side effects
- Possible anti-tumor activity (preclinical)
- Generally well tolerated
Potential concerns
- Possible increase in aromatase activity (estrogen production)
- Possible interaction with endocrine therapy
- Limited breast-cancer–specific clinical trials
- Supplement quality variability
However, larger clinical trials are still needed to confirm its role in cervical cancer prevention or treatment.
Research References
- https://pubmed.ncbi.nlm.nih.gov/35814366/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC9256908/
- https://pmc.ncbi.nlm.nih.gov/articles/PMC6435520/
- AHCC and Cervical Cancer AHCC and Cervical Cancer
To Learn More About Complementary Therapies